Furthermore, a clinical development program by BioSeedin is evaluating a selective c-Met/Axl inhibitor in a Phase I trial specifically enrolling gastric cancer patients; although published trial identifiers are not yet available, GlobalData confirms this candidate is in early-phase testing for GC. Here, MET is linked to gastric cancer.